Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase II Trial of Capecitabine (Xeloda) in Combination With Cisplatin as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma

NCT02608073 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02608073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02608073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase II Trial of Capecitabine (Xeloda) in Combination With Cisplatin as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
November 30, 2009
Enrollment
45 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer